M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
β Scribed by De Souza, Angus T.; Hankins, Gerald R.; Washington, Mary K.; Orton, Terry C.; Jirtle, Randy L.
- Book ID
- 109918894
- Publisher
- Nature Publishing Group
- Year
- 1995
- Tongue
- English
- Weight
- 549 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1061-4036
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) suppresses cell growth through binding to the insulin-like growth factor 2 (IGF2) and latent complex of the transforming growth factor-β€ (TGF-β€). Recently, it was reported in the United States that loss of heterozygosity (LOH)
Wilms tumor (WT) is a kidney malignancy of childhood characterized by highly heterogeneous genetic alterations. We previously reported the molecular and cytogenetic characterization of a WT (Case 30) carrying an interstitial deletion in chromosome 7p14 between markers D7S555 and D7S668. Loss of hete
## Abstract To elucidate whether the M6p/Igf2 receptor (M6p/Igf2r) gene might be involved in exogenous and endogenous liver carcinogenesis, we investigated its alteration in hepatocellular carcinomas (HCCs) induced by __N__βnitrosodiethylamine (DEN) and by a cholineβdeficient Lβamino acidβdefined (